Stem Cell & Organoid Research

Pipeline for investigating stem cell biology, iPSC characterization, organoid models, and cell differentiation using ToolUniverse tools.

Reasoning Strategy

Stem cell differentiation follows developmental biology — to make any target cell type from iPSCs, the protocol must mimic the embryonic signaling pathway that generates that cell type in vivo. For neural induction: inhibit BMP and TGF-beta (dual SMAD inhibition). For cardiomyocytes: activate WNT then inhibit WNT. For pancreatic beta cells: activate Activin/Nodal → FGF → Notch inhibition → BMP in sequence. The order and timing of growth factors matters critically — adding BMP4 during neural induction will redirect cells toward mesoderm. Mouse and human stem cells differ in their signaling requirements (LIF/STAT3 for mouse naive pluripotency; FGF/ERK for human primed pluripotency), so protocols are not interchangeable. Organoids recapitulate some but not all organ features — always assess maturation state (fetal vs. adult gene expression) before drawing disease-relevance conclusions.

LOOK UP DON'T GUESS: Do not assume which markers define a target cell type or which signaling pathway drives differentiation — query CellMarkersearchbycelltype for markers and keggsearchpathway for the relevant pathway. Do not assume organoid fidelity; look up published CellxGene or HCA atlas data for comparison.

Key principles:

1. Marker-based identity — stem cell identity is defined by marker expression profiles (OCT4, SOX2, NANOG for pluripotency)
2. Differentiation is a trajectory — not a binary state; analyze intermediate progenitor stages
3. Organoid ≠ organ — organoids recapitulate some but not all organ features; always note limitations
4. Species matters — mouse and human stem cells differ in signaling requirements
5. Evidence grading — T1: validated in clinical iPSC study, T2: functional assay (teratoma, engraftment), T3: marker expression only, T4: computational prediction

Core Tools

Workflow

Phase 0: Define the Question
  Pluripotency? Differentiation? Disease modeling? Drug screening?
    |
Phase 1: Cell Identity & Markers
  CellMarker → pluripotency/lineage markers → verify identity
    |
Phase 2: Differentiation Pathways
  KEGG/Reactome → WNT, Notch, BMP, FGF signaling
    |
Phase 3: Atlas & Dataset Discovery
  CellxGene/HCA → reference datasets for target cell type
    |
Phase 4: Disease Modeling (if applicable)
  OpenTargets → disease genes → organoid recapitulation assessment
    |
Phase 5: Report
  Evidence-graded findings with clinical translation potential

Phase 1: Cell Identity & Markers

Pluripotency markers (must be co-expressed): OCT4 (POU5F1), SOX2, NANOG (essential); SSEA-4, TRA-1-60 (human surface markers). KLF4 and MYC are Yamanaka factors but also expressed in somatic cells — do not rely on them alone. Use CellMarkersearchbycelltype to retrieve the full validated marker set for any target cell type.

Lineage markers: Ectoderm → PAX6/SOX1 (early), MAP2/TUBB3 (neurons); Mesoderm → TBXT/MIXL1 (early), CD34 (blood); Endoderm → SOX17/FOXA2 (early), PDX1/NKX6.1 (pancreas). Retrieve current marker lists from CellMarker rather than relying on memory.

Phase 2: Differentiation Pathways

Key signaling pathways for directed differentiation:

Phase 3: Atlas & Dataset Discovery

# Find stem cell single-cell datasets
CELLxGENE_get_census_versions()  # discover available Census releases, then use CELLxGENE_get_cell_metadata / CELLxGENE_get_expression_data
hca_search_projects(query="organoid")
GEO_search_rnaseq_datasets(query="iPSC differentiation neural", organism="Homo sapiens")

Phase 4: Organoid Model Assessment

Organoid fidelity scoring — how well does the organoid recapitulate the organ?

Evidence Grading

Synthesis Questions

1. Is the cell identity verified? (co-expression of 3+ pluripotency markers, or lineage-appropriate markers)
2. Is the differentiation protocol reproducible? (published, peer-reviewed, with quantified efficiency)
3. Does the organoid model the disease? (patient-derived iPSC shows disease phenotype in organoid)
4. What are the translational barriers? (scalability, maturation, immune compatibility, tumorigenicity)
5. What's the best reference dataset? (CellxGene atlas for comparison)

Limitations

• No organoid protocol database — protocols are scattered across publications; use PubMed search
• Maturation gap — most organoids resemble fetal, not adult tissue; always note maturation state
• Batch variability — iPSC-derived cells vary between passages and donor lines
• No direct culture tools — this skill analyzes published data and designs experiments; it does not control bioreactors
• Species differences — mouse ESCs require LIF; human ESCs require bFGF. Don't mix protocols